Literature DB >> 36104415

Metastatic prostate cancer: seeking a fresh chance of recovery.

Charlie Schmidt.   

Abstract

Entities:  

Keywords:  Cancer; Imaging; Therapeutics

Mesh：

Year:  2022        PMID： 36104415     DOI： 10.1038/d41586-022-02859-6

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   69.504


× No keyword cloud information.
  5 in total

1.  Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.

Authors:  Chris C Parker; Nicholas D James; Christopher D Brawley; Noel W Clarke; Adnan Ali; Claire L Amos; Gerhardt Attard; Simon Chowdhury; Adrian Cook; William Cross; David P Dearnaley; Hassan Douis; Duncan C Gilbert; Clare Gilson; Silke Gillessen; Alex Hoyle; Rob J Jones; Ruth E Langley; Zafar I Malik; Malcolm D Mason; David Matheson; Robin Millman; Mary Rauchenberger; Hannah Rush; J Martin Russell; Hannah Sweeney; Amit Bahl; Alison Birtle; Lisa Capaldi; Omar Din; Daniel Ford; Joanna Gale; Ann Henry; Peter Hoskin; Mohammed Kagzi; Anna Lydon; Joe M O'Sullivan; Sangeeta A Paisey; Omi Parikh; Delia Pudney; Vijay Ramani; Peter Robson; Narayanan Nair Srihari; Jacob Tanguay; Mahesh K B Parmar; Matthew R Sydes
Journal:  PLoS Med       Date:  2022-06-07       Impact factor: 11.613

2.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Authors:  Piet Ost; Dries Reynders; Karel Decaestecker; Valérie Fonteyne; Nicolaas Lumen; Aurélie De Bruycker; Bieke Lambert; Louke Delrue; Renée Bultijnck; Tom Claeys; Els Goetghebeur; Geert Villeirs; Kathia De Man; Filip Ameye; Ignace Billiet; Steven Joniau; Friedl Vanhaverbeke; Gert De Meerleer
Journal:  J Clin Oncol       Date:  2017-12-14       Impact factor: 44.544

3.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Authors:  Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Robert R Flavell; Ashley Mishoe; Felix Y Feng; Hao G Nguyen; Robert E Reiter; Matthew B Rettig; Shozo Okamoto; Louise Emmett; Helle D Zacho; Harun Ilhan; Axel Wetter; Christoph Rischpler; Heiko Schoder; Irene A Burger; Jeannine Gartmann; Raven Smith; Eric J Small; Roger Slavik; Peter R Carroll; Ken Herrmann; Johannes Czernin; Thomas A Hope
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

4.  Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer.

Authors:  D K Reyes; S P Rowe; E M Schaeffer; M E Allaf; A E Ross; C P Pavlovich; C Deville; P T Tran; K J Pienta
Journal:  Med Oncol       Date:  2020-06-10       Impact factor: 3.064

5.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.

Authors:  Ryan Phillips; William Yue Shi; Matthew Deek; Noura Radwan; Su Jin Lim; Emmanuel S Antonarakis; Steven P Rowe; Ashley E Ross; Michael A Gorin; Curtiland Deville; Stephen C Greco; Hailun Wang; Samuel R Denmeade; Channing J Paller; Shirl Dipasquale; Theodore L DeWeese; Daniel Y Song; Hao Wang; Michael A Carducci; Kenneth J Pienta; Martin G Pomper; Adam P Dicker; Mario A Eisenberger; Ash A Alizadeh; Maximilian Diehn; Phuoc T Tran
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.